Hypothesis: A possible role for interferon in the treatment of idiopathic myelofibrosis

H. Hasselbalch*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    It is proposed that interferon may be an active agent in the treatment of patients with idiopathic myelofibrosis. In this disorder the megakaryocyte cell lineage plays a major role in the deposition of bone marrow collagen by the release of growth promoting factors, including platelet-derived growth factor, which are mitogenic for fibroblast proliferation. Interferon reduces collagen deposition in the bone marrow by suppressing the activity of the proto-oncogene, which is involved in the production of growth factors from abnormal megakaryocytes and platelets. A direct myeloid cytoreductive effect of interferon upon the megakaryocyte proliferation contributes to reducing growth factor activity in the bone marrow. Finally, interferon induces monocytoid differentiation, thereby increasing bone marrow collagenase-activity. Thus, interferon has several actions, which in concert might reduce bone marrow collagen in myelofibrosis.

    OriginalsprogEngelsk
    Sider (fra-til)345-347
    Antal sider3
    TidsskriftMedical Hypotheses
    Vol/bind27
    Udgave nummer4
    DOI
    StatusUdgivet - dec. 1988

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Hypothesis: A possible role for interferon in the treatment of idiopathic myelofibrosis' indeholder.

    Citationsformater